News & Insights

The Israeli Supreme Court has rendered its important and controversial decision in the Sanofi v. Unipharm case, holding that a Patent Applicant who intentionally deceives the Patent Office in order to obtain a patent, may be liable, under the Israeli law of unjust enrichment, to pay generic competitors who delayed entering the market at risk because of this patent application, restitution of the profits gained at their expense as a result of this deception.

In the four decades that have passed since the fatal AIDS disease erupted in 1981, considerable efforts were and continue to be invested into developing treatments. This has been largely successful. Today AIDS is no longer a life-threatening disease. The first breakthrough occurred when scientists succeeded in identifying the virus…

The unprecedented success of the COVID-19 vaccines, both therapeutically and commercially, has prompted fierce competition. Multiple companies around the world are fighting to claim patent rights related to these vaccines.

As the New York Times recently reported, ten years have passed since the first publication of a ground-breaking paper about the potential usefulness of CRISPR, “the gene-editing technology [that] has led to innovations in medicine, evolution and agriculture — and raised profound ethical questions about altering human DNA.”